Global Peptide Therapeutics Market Report 2022: Adoption of New Platforms That Develop Next-Generation Protein or Peptide Therapeutics Drives Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Peptide Therapeutics Market (2022-2027) by Synthesis Technology, Drug Class, Route of Administration, API Type, Application, End User, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.

The Global Peptide Therapeutics Market is estimated to be USD 29.84 Bn in 2022 and is expected to reach USD 48.19 Bn by 2027, growing at a CAGR of 10.06%.

Market Segmentations

The Global Peptide Therapeutics Market is segmented based on Synthesis Technology, Drug Class, Route of Administration, API Type, Application, End User, and Geography.

• By Synthesis Technology, the market is classified into Hybrid Phase, Liquid Phase, and Solid Phase.
• By Drug Class, the market is classified into Calcitonin’s, Glucagon & Analogs, Insulins, Luteinizing Hormone-Releasing Hormone, Somatostatins, and Vasopressin.
• By Route of Administration, the market is classified into Parenteral and Oral.
• By API Type, the market is classified into CMO and In-house.
• By Application, the market is classified into Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, and Other Applications.
• By End User, the market is classified into Hospitals, Pharmaceutical Industries, and Research Laboratories.
• By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Peptide Therapeutics Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The analyst analyses the Global Peptide Therapeutics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Market Dynamics

Drivers

• Increasing Prevalence of Cancer, Cardiovascular Disorders, and Metabolic Disorders
• Adoption of New Platforms That Develop Next-Generation Protein or Peptide Therapeutics

Restraints

• Poor Chemical and Physical Stability and a Short Circulating Plasma Half-Life of Naturally Occurring Peptides

Opportunities

• Technology Advancement and R&D Investment in New Peptides
• Presence of a Strong Product Pipeline Portfolio

Challenges

• Presence of Stringent Safety Regulations

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Dynamics

5 Market Analysis

6 Global Peptide Therapeutics Market, By Synthesis Technology

7 Global Peptide Therapeutics Market, By Drug Class

8 Global Peptide Therapeutics Market, By Route of Administration

9 Global Peptide Therapeutics Market, By API Type

10 Global Peptide Therapeutics Market, By Application

11 Global Peptide Therapeutics Market, By End User

12 Americas’ Peptide Therapeutics Market

13 Europe’s Peptide Therapeutics Market

14 Middle East and Africa’s Peptide Therapeutics Market

15 APAC’s Peptide Therapeutics Market

16 Competitive Landscape

17 Company Profiles

18 Appendix

Companies Mentioned

• AmbioPharm Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bachem Holding Ag
• Bristol-Myers Squibb Company
• Corden Pharma GmbH
• Eli Lilly and Company
• F. Hoffmann-La Roche Ag
• GSK PLC
• Hemmo Pharmaceuticals Pvt. Ltd.
• Ipsen SA
• Merck & Co., Inc.
• Novartis International Ag
• Novo Nordisk AS
• Pfizer Inc.
• PolyPeptide Group
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zealand Pharma AS

For more information about this report visit https://www.researchandmarkets.com/r/3lc85y

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900